Heart failure & cardiomyopathies
Improved outcome up to 10 years after intravenous immunoglobulin therapy in patients with dilated cardiomyopathy
Authors' conclusion
In patients with DCM and cardiac B19V persistence, IVIg added to GDMT correlated with improved long-term clinical outcome.
Study context
- Population
- Patients with dilated cardiomyopathy (DCM) and cardiac parvovirus-B19 (B19V) persistence
- Participants
- 50 patients
- Comparison
- IVIg added to guideline-directed medical therapy (GDMT) vs placebo
- IVIgn = 26
- Placebon = 24reference
- Primary endpoint
- Composite of:
- Cardiac death
- HF hospitalization
- Life-threatening arrhythmia
- Follow-up
- Median 6.8 [5.6-10.3] years
Methodological detailsblinded, placebo-controlled
- Blinded
- Placebo-controlled
Primary result
As reported in the abstract
Composite endpoint:
- Cardiac death
- HF hospitalization
- Life-threatening arrhythmia
IVIg
1/26
1 of 26
Placebo
8/24
8 of 24
P = 0.0075
Further findings
Endomyocardial biopsy single-nuclear RNA sequencing (snRNA-seq), baseline vs 6 months
- IVIg reduced cardiac monocyte infiltration and, unlike placebo, prevented expansion of injured cardiomyocytes
- IVIg induced transcriptomic reprogramming: diminished myeloid-to-fibroblast signaling with reduced TGFβ activity, decreased pro-fibrotic and pro-inflammatory pathways, enhanced oxidative phosphorylation in cardiomyocytes
Original publication
Improved outcome up to 10 years after intravenous immunoglobulin therapy in patients with dilated cardiomyopathy. Eur J Heart Fail. Published 15 May 2026. doi:10.
Summarised from the published abstract; every number is checked against it